Header Logo

Connection

SANJAY MATHEW to Excitatory Amino Acid Antagonists

Back to Details
This is a "connection" page, showing publications SANJAY MATHEW has written about Excitatory Amino Acid Antagonists.
SANJAY MATHEW
Connection Strength
3.383
Excitatory Amino Acid Antagonists
  1. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518.
    View in: PubMed
    Score: 0.567
  2. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42.
    View in: PubMed
    Score: 0.404
  3. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012 Mar 01; 26(3):189-204.
    View in: PubMed
    Score: 0.362
  4. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009 Sep 01; 66(5):522-6.
    View in: PubMed
    Score: 0.302
  5. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010 Feb; 13(1):71-82.
    View in: PubMed
    Score: 0.295
  6. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry. 2008 May 01; 63(9):891-8.
    View in: PubMed
    Score: 0.268
  7. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005 Dec; 162(12):2379-81.
    View in: PubMed
    Score: 0.235
  8. Glutamate modulators as novel interventions for mood disorders. Braz J Psychiatry. 2005 Sep; 27(3):243-8.
    View in: PubMed
    Score: 0.232
  9. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 02 01; 175(2):150-158.
    View in: PubMed
    Score: 0.133
  10. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul; 16(7):472-486.
    View in: PubMed
    Score: 0.128
  11. Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. Curr Psychiatry Rep. 2015 Oct; 17(10):81.
    View in: PubMed
    Score: 0.116
  12. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar; 76(3):247-52.
    View in: PubMed
    Score: 0.112
  13. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008 May 15; 148C(2):89-98.
    View in: PubMed
    Score: 0.070
  14. One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 05 01; 6(5):e2312434.
    View in: PubMed
    Score: 0.049
  15. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022 12 01; 179(12):959-968.
    View in: PubMed
    Score: 0.047
  16. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019 11 01; 176(11):923-930.
    View in: PubMed
    Score: 0.038
  17. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Neurosci Lett. 2012 Nov 14; 530(1):103-7.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.